# Junta clínica — PT-pseudo_d38917f87b35 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_d38917f87b35",
  "pid": "PT-pseudo_d38917f87b35",
  "task": 1,
  "psa": 28.3,
  "age": 61,
  "months": 2,
  "pirads": "5",
  "psad": 0.4,
  "psav": -0.78,
  "psap": 25.3,
  "vol": 70.0,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.8709831,
  "medhx": "Type 2 diabetes, Hypercholesterolaemia",
  "meds": "empagliflozin, simvastatin, rosuvastatin",
  "notes": "PSA 28.3 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 70 mL. DRE nodus. csPCa 0.87.",
  "pmhx": [
    "Type 2 diabetes",
    "Hypercholesterolaemia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "99 kg",
    "height": "177 cm",
    "bmi": "31.6",
    "bp": "126/68 mmHg",
    "hr": "67 bpm",
    "smoking": "Ex-smoker (23 pack-yr, quit 2015)",
    "last_dental": "2 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "11 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Rising prostate-specific antigen levels to 28.3 ng/mL alongside a confirmed prior malignancy prompt this clinical review."
    },
    {
      "s": "History",
      "t": "A 61-year-old retired firefighter initiated urological workup in mid-2023 after an elevated screening result, leading to a systematic biopsy that confirmed a Positive finding of ISUP GG5 disease. Currently residing with his partner as a widowed individual, the patient maintains a rigorous exercise regimen of three 5-kilometre runs per week. Lower urinary tract complaints have increased, pushing his IPSS score to 19 out of 35. Past medical records highlight well-managed type 2 diabetes under empagliflozin therapy, alongside hypercholesterolaemia addressed with simvastatin and rosuvastatin. He successfully ceased smoking after accumulating 23 pack-years, having quit in 2015. Additional surgical history includes a meniscectomy on the right knee performed during his firefighting career, and he recently finished a six-session physiotherapy course for mechanical back pain that remains independent of his urological status. An adult son handles his primary medical communications, and morning appointments are preferred to align with his public transit routine."
    },
    {
      "s": "Physical examination",
      "t": "DRE: The prostate presents as asymmetrically enlarged, featuring a distinct, firm nodule within the left peripheral zone. Systemic assessment shows stable hemodynamics and a body mass index of 31.6. Abdominal palpation detects no masses, and cervical or inguinal lymph nodes remain non-palpable."
    }
  ],
  "occupation": "retired firefighter",
  "marital": "Widowed",
  "living": "Lives with partner",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Physiotherapy — lower back, six sessions"
  ],
  "alcohol": "12 units / week",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 19/35 (moderate LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "Radboudumc",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d38917f87b35
Task: 1

Encounter: Urology - outpatient on 11 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 61-year-old male
  - PSA: 28.3 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.4 ng/mL²
  - PSA velocity: -0.78 ng/mL/yr
  - Prior PSA: 25.3 ng/mL
  - Prostate volume: 70.0 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8709831 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Hypercholesterolaemia
  - Problem list / PMHx: Type 2 diabetes, Hypercholesterolaemia
  - Current medication: empagliflozin, simvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 28.3 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 70 mL. DRE nodus. csPCa 0.87.

Vitals: weight 99 kg, height 177 cm, BMI 31.6, BP 126/68 mmHg, HR 67 bpm. Smoking: Ex-smoker (23 pack-yr, quit 2015).

Chief complaint: Rising prostate-specific antigen levels to 28.3 ng/mL alongside a confirmed prior malignancy prompt this clinical review.

History: A 61-year-old retired firefighter initiated urological workup in mid-2023 after an elevated screening result, leading to a systematic biopsy that confirmed a Positive finding of ISUP GG5 disease. Currently residing with his partner as a widowed individual, the patient maintains a rigorous exercise regimen of three 5-kilometre runs per week. Lower urinary tract complaints have increased, pushing his IPSS score to 19 out of 35. Past medical records highlight well-managed type 2 diabetes under empagliflozin therapy, alongside hypercholesterolaemia addressed with simvastatin and rosuvastatin. He successfully ceased smoking after accumulating 23 pack-years, having quit in 2015. Additional surgical history includes a meniscectomy on the right knee performed during his firefighting career, and he recently finished a six-session physiotherapy course for mechanical back pain that remains independent of his urological status. An adult son handles his primary medical communications, and morning appointments are preferred to align with his public transit routine.

Physical examination: DRE: The prostate presents as asymmetrically enlarged, featuring a distinct, firm nodule within the left peripheral zone. Systemic assessment shows stable hemodynamics and a body mass index of 31.6. Abdominal palpation detects no masses, and cervical or inguinal lymph nodes remain non-palpable.

Patient info: retired firefighter; Widowed; Lives with partner.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 12 units / week; exercise Running 3x/week, 5 km; IPSS score: 19/35 (moderate LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.55
  uncertainty  +/- 0.08 epistemic (95% band 0.38-0.71); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PSA >= 20 ng/mL in a man with a tissue diagnosis: the next step is staging and treatment, not more tissue. In the labelled series this criterion matched the reading urologist in 5 of 6 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.30: PI-RADS 5, PSA 10.92, PSAD 0.26, age 61, DRE Nodus -> DEFER (clear). He wrote: "Advocate for curative treatment while unfavorable intermediate risk pc in young patient without significant comorbidity. IF he is cautious toward curative treatment, rep…"
  2. distance 1.76: PI-RADS 5, PSA 19.0, PSAD 0.37, age 65, DRE Normal -> DEFER (clear). He wrote: "Patient needs treatment without repeat biopsy as earlier biopsy showed ISUP4"
  3. distance 1.82: PI-RADS 5, PSA 8.3, PSAD 0.215, age 66, DRE Suspicious -> DEFER (clear). He wrote: "This person should discuss curative treatment (younger patient with palpable, MRI-visible high-risk disease incl Gleason 5 findings). If not curative treatment for any r…"

PRECEDENT: DEFER (weighted vote 0.00 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=decisive, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines address the management of prostate cancer in men with a prior diagnosis. For patients with a prior positive biopsy, the guideline suggests that the management should be guided by the current clinical situation and the risk stratification of the lesion identified on imaging. "If the patient has a prior positive biopsy, the decision to pursue further biopsy should be based on the current clinical context, including the current PSA level, the mpMRI findings, and the clinical suspicion for clinically significant cancer."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline requires the decision to be based on the current clinical context, which is not fully established by the panel alone. Expert 4's trace model suggests weighing the prior biopsy and DRE heavily, but the guideline mandates that the decision must incorporate the current PSA level and mpMRI findings to determine the clinical context.

WHAT WE STILL NEED
The guideline requires establishing the current clinical context based on the patient's data.
Prior biopsy status: Positive (from panel).
Current PSA: 28.3 ng/mL (from panel).
mpMRI finding: PI-RADS 5 (from panel).
Months since last PSA: 2 (from panel).
Prior biopsy result: Positive (from panel).

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the current clinical context as required by the EAU guideline, specifically integrating the high-risk imaging findings with the elevated PSA.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the specific description of the lesion size and zone from the radiology report?
  psa_trend (get_psa_trend) -> What is the trend of the serial PSA values?
  previous_notes (get_previous_notes) -> What is the management context regarding the prior biopsy, including the grade (Gleason/ISUP), surveillance status, and planned treatment?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the specific description of the lesion size and zone from the radiology report?
  Q2. What is the trend of the serial PSA values?
  Q3. What is the management context regarding the prior biopsy, including the grade (Gleason/ISUP), surveillance status, and planned treatment?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The specific description of the lesion size and zone from the radiology report: "A discrete abnormality localizes to the left peripheral zone, spanning the base through mid-gland, measuring roughly 28 mm longest diameter."
psa_trend
The trend of the serial PSA values: [{"date": "Jul 2023", "val": 1.3}, {"date": "Dec 2023", "val": 19.1}, {"date": "Apr 2024", "val": 9.0}, {"date": "Aug 2024", "val": 9.7}, {"date": "Jan 2025", "val": 28.3}]
previous_notes
The management context regarding the prior biopsy, including the grade (Gleason/ISUP), surveillance status, and planned treatment: "Following a December 2023 PSA measurement of 22.4 ng/mL, a consultation addressed the recent prostate cancer diagnosis and the significance of the earlier biopsy results. Discussion centered on the pathological features and general prognosis."

WHAT I DID NOT OPEN
family-history anamnesis, because the information was not required to establish the current clinical context as per the EAU guideline.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
mpMRI finding: PI-RADS 5
Current PSA: 28.3 ng/mL
psa_trend: The serial PSA values show a significant rise, culminating in 28.3 ng/mL in January 2025.

Findings that argue AGAINST sampling this patient now:
Prior biopsy status: Positive
Cohort criterion: PSA >= 20 ng/mL in a man with a tissue diagnosis suggests staging and treatment over further tissue.

WHERE THIS LEANS
The data strongly supports the need to establish the current clinical context, as required by the EAU guideline, by showing a high-risk MRI finding and a significantly elevated PSA.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 28.30 ng/mL over 5 points spanning 18 months; velocity +12.71 ng/mL per year; doubling time about 5 months.
PROJECTION at 6 months: 83.4 ng/mL, conformal 95% band 23.9-290.5.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.49
  uncertainty  +/- 0.08 epistemic (95% band 0.33-0.64), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 59% of the time over the 29 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.55  ('discuss' tier)
  EXPERT-FUSION      DEFER, p(biopsy)=0.49  ('discuss' tier, fusion_nolab)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.00  (k=3 precedents)
  EXPERT-COHORT      DEFER  (rule psa_ge_20)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (psa_ge_20) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 5 of 6 labelled cases in exactly this situation (prior positive biopsy).
Dissenting on the board: EXPERT-STRUCTURED. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

Confidence the trace model expects here: clear. Weights it expects: bx=decisive, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, and previous_notes—directly address all three moderator questions.

ALIGNMENT WITH THE PANEL
The Panel Protocol's answer is NO BIOPSY, which is supported by the EXPERT-COHORT rule (PSA $\ge 20$ ng/mL) which fired. The retrieved data supports this by showing a rising PSA trend culminating at 28.3 ng/mL.

THE OPEN QUESTIONS, ONE BY ONE
Q1. The specific description of the lesion size and zone is answered by the radiology report: "A discrete abnormality localizes to the left peripheral zone, spanning the base through mid-gland, measuring roughly 28 mm longest diameter."
Q2. The trend of the serial PSA values is answered by the psa_trend document, showing a significant rise to 28.3 ng/mL in January 2025.
Q3. The management context regarding the prior biopsy is partially answered by the previous_notes, which mention a consultation regarding the prior diagnosis and pathological features, but the specific Gleason/ISUP grade is not explicitly stated in the retrieved text.

WHAT CARRIES WEIGHT, AND WHY
The current PSA level (28.3 ng/mL) and the PI-RADS 5 finding from the panel are highly relevant because they establish the current high-risk clinical context. The cohort criterion (PSA $\ge 20$ ng/mL) is the explicit rule that led to the Panel Protocol's decision.

MY SUGGESTION TO THE CHAIR
The evidence retrieved confirms the high-risk context (PI-RADS 5, PSA 28.3) and the cohort criterion is met, supporting the Panel Protocol's decision to defer biopsy in favor of staging and treatment.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

Decision to defer biopsy for a 61-year-old man with PI-RADS 5, PSA 28.3 ng/mL, PSA density 0.4 and a prior biopsy status of 'Positive'. The panel protocol settled it by the rule 'cohort criterion (psa_ge_20)' (EXPERT-COHORT); It matched the reading urologist in 5 of 6 labelled cases in exactly this situation (prior positive biopsy). The conference did not return a readable structured form, so this record was completed from the minute alone; no finding is asserted beyond the values in it.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
[completed by the deterministic fallback: the form did not validate]
